✦ LIBER ✦

Clinical subgroups and antifungal susceptibilities in fungal culture-positive patients with chronic rhinosinusitis

✍ Scribed by Selim S. Erbek; Kivanc Serefhanoglu; Seyra Erbek; Muge Demirbilek; Fusun Can; Erkan Tarhan; Hale Turan; Ozcan Cakmak

Publisher: Springer-Verlag
Year: 2007
Tongue: English
Weight: 256 KB
Volume: 265
Category: Article
ISSN: 0302-9530
DOI: 10.1007/s00405-007-0542-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The breakpoint cluster region site in pa

The breakpoint cluster region site in patients with Philadelphia chromosome–positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations

✍ Claire F. Verschraegen; Hagop M. Kantarjian; Cherryl Hirsch-Ginsberg; Ming S. Le 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 608 KB

Is anti-hbc IgM a useful clinical test i

Is anti-hbc IgM a useful clinical test in patients with HBsAg-positive chronic hepatitis or primary hepatocellular carcinoma?

✍ Min Chan Lai; Myron J. Tong; Marek J. Nowicki; Shou-Dong Lee 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 508 KB

Seventy HBsAg-positive patients, including 24 with primary hepatocellular carcinoma, 34 with chronic active hepatitis, 12 with chronic persistent hepatitis and 30 asymptomatic healthy hepatitis B virus carriers were tested for anti-HBc IgM using the Corzyme-M test. Anti-HBc IgM was detected in 50% o

Multifactorial central nervous system re

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer : Epidemiological and clinical data from a population-based cancer registry study

✍ Antonino Musolino; Laura Ciccolallo; Michele Panebianco; Elisa Fontana; Daniele 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB 👁 2 views

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH